Nishimura K, Soda T, Nakazawa S, Yamanaka K, Hirai T, Kishikawa H, Ichikawa Y
Department of Urology, Hyogo Prefectural Nishinomiya Hospital Nishinomiya, Japan.
Minerva Urol Nefrol. 2012 Sep;64(3):199-208.
Adiponectin and leptin, polypeptide hormones produced by adipocytes, have recently been reported to be associated with prostate cancer risk, though, the relationship remains poorly understood. We examined the association of adiponectin and leptin levels in serum with prostate cancer risk after adjustments for age, obesity-related factors, and prostate cancer risk.
Fifty-four prostate cancer patients and 70 control subjects provided blood sampled between 2008 and 2009. Using those, we determined serum adiponectin and leptin levels, and evaluated their relationships with prostate cancer risk after adjustments for age, obesity-related factors (body weight, body mass index, waist circumference), and prostate volume. Adipokine densities were calculated by dividing serum level with prostate volume.
There were no differences for median serum adiponectin and leptin levels between the prostate cancer and benign control groups (P=0.22 and 0.78, respectively). Patients with levels of both adipokines in the highest quartile after adjustment for age had significantly higher risks of prostate cancer (adiponectin: odds ratio [OR] 2.79, P=0.014; leptin: OR 2.72, P=0.027). Patients with an adiponectin level greater than the median after adjustment for body weight also had a significantly elevated risk of prostate cancer (OR 2.22, P=0.031), whereas, those with a leptin level significantly greater than the median had a significantly lower risk (OR 0.46, P=0.027). Furthermore, median adiponectin density was significantly higher in the prostate cancer group than the benign group (P=0.0033).
Serum adiponectin and leptin levels are useful markers for prostate cancer risk after adjustments for age, obesity-related factors, and prostate volume.
脂联素和瘦素是脂肪细胞产生的多肽激素，最近有报道称它们与前列腺癌风险有关，不过，这种关系仍未得到充分理解。我们在对年龄、肥胖相关因素和前列腺癌风险进行调整后，研究了血清中脂联素和瘦素水平与前列腺癌风险的关联。
54例前列腺癌患者和70例对照受试者于2008年至2009年期间提供了血液样本。利用这些样本，我们测定了血清脂联素和瘦素水平，并在对年龄、肥胖相关因素（体重、体重指数、腰围）和前列腺体积进行调整后，评估了它们与前列腺癌风险的关系。通过将血清水平除以前列腺体积来计算脂肪因子密度。
前列腺癌组和良性对照组之间血清脂联素和瘦素水平的中位数没有差异（分别为P = 0.22和0.78）。在对年龄进行调整后，两种脂肪因子水平均处于最高四分位数的患者患前列腺癌的风险显著更高（脂联素：比值比[OR] 2.79，P = 0.014；瘦素：OR 2.72，P = 0.027）。在对体重进行调整后，脂联素水平高于中位数的患者患前列腺癌的风险也显著升高（OR 2.22，P = 0.031），而瘦素水平显著高于中位数的患者患前列腺癌的风险则显著降低（OR 0.46，P = 0.027）。此外，前列腺癌组的脂联素密度中位数显著高于良性组（P = 0.0033）。
在对年龄、肥胖相关因素和前列腺体积进行调整后，血清脂联素和瘦素水平是前列腺癌风险的有用标志物。
